Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6496 to 6510 of 7707 results

  1. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    In development [GID-HST10032] Expected publication date: TBC

  2. Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

    Discontinued [GID-HST10004]

  3. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued [GID-TA10310]

  4. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued [GID-TAG432]

  5. Omburtamab for treating relapsed neuroblastoma [ID1664]

    In development [GID-TA10608] Expected publication date: TBC

  6. Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]

    Discontinued [GID-TA10341]

  7. Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

    Discontinued [GID-TAG423]

  8. Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]

    In development [GID-TAG499] Expected publication date: TBC

  9. Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

    Discontinued [GID-TA10164]

  10. Constipation (opioid induced) - lubiprostone [ID646]

    Discontinued [GID-TAG367]

  11. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued [GID-HST10007]

  12. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued [GID-TAG507]

  13. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued [GID-IP1041]

  14. Pacritinib for treating myelofibrosis [ID880]

    Discontinued [GID-TA10133]